Atai Goes Public With Promising New Mental-Health Treatments Based On Psychedelics
Kate Stalter
Germany-based Atai Life Sciences (NASDAQ: ATAI), a biotech backed by Peter Thiel, a founder of PayPal, made its public debut Friday. Atai focuses on the use of psychedelics to treat mental health conditions. It’s considered a clinical-stage biotech. The company does not yet have regulators’ OK to move forward with treatments.
NASDAQ:ATAINASDAQ:MNMDNASDAQ:CMPS